Document is current

Article History

Received: 20 September 2021

Accepted: 8 May 2022

First Online: 23 May 2022

Declarations

:

: The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01- AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, in four clinical sites (University of Maryland School of Medicine and Johns Hopkins University, Baltimore, MD; Ohio State University, Columbus, OH; University of Pittsburgh, PA; Memorial Hospital of Rhode Island, Pawtucket, RI) and conducted by the OAI study investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health, USA. All OAI participants provided written informed consent for participation in the OAI. Ethics approval was obtained by each OAI clinical site (University of Maryland Baltimore -Institutional Review Board, Ohio State University’s Biomedical Sciences Institutional Review Board, University of Pittsburgh Institutional Review Board, and Memorial Hospital of Rhode Island Institutional Review Board) and the OAI coordinating center (Committee on Human Research at the University of California, San Francisco, CA, USA [#10-00532]). For the NFOAS cohort, the ethics approval was from the Health Research Ethics Board of Newfoundland and Labrador [HREB #2011.311]. The Institutional Ethics Committee Board of the University of Montreal Hospital Research Centre [#BD04.001] approved the use of the human serum.

: All authors had full access to the data and take responsibility for the integrity of the data and the accuracy of the data analysis.

: The authors declare that they have no competing interests.